Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor

Tumor Biology

Volumn 36, Issue 4, 2015, Pages 2607-2612

  Li, Shaoyi ^a,b   Guo, Wenchang ^a,b   Gao, Yun ^a,b   Liu, Yunhui ^a,b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b He Eye Industry Group Co LTD   (China)

Author keywords

Epidermal growth factor receptor (EGFR); Ginsenoside Rh2 (GRh2); Glioblastoma multiforme (GBM); mTor; PI3k

Indexed keywords

2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GINSENOSIDE; GINSENOSIDE RH 2; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; TARGET OF RAPAMYCIN KINASE;

BRAIN NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; GLIOBLASTOMA; HUMAN; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; GINSENOSIDES; GLIOBLASTOMA; HUMANS; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84936741690     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2880-2     Document Type: Article

References (33)

1. Chen J, Huang Q, Wang F. Inhibition of FoxO1 nuclear exclusion prevents metastasis of glioblastoma. Tumour Biol. 2014;35:7195–200.
2. Wang F, Xiao W, Sun J, Han D, Zhu Y. Mirna-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol. 2014;35:8653–8.
3. Gong J, Zhu S, Zhang Y, Wang J. Interplay of VEGFa and MMP2 regulates invasion of glioblastoma. Tumour Biol. 2014. doi:10.1007/s13277-014-2438-3.
4. Tian XX, Chan JY, Pang JC, Chen J, He JH, To TS, et al. Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor. Br J Cancer. 1999;81:994–1001.
5. Tsatas D, Kanagasundaram V, Kaye A, Novak U. EGF receptor modifies cellular responses to hyaluronan in glioblastoma cell lines. J Clin Neurosci. 2002;9:282–8.
6. Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, et al. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 (‘iressa’). Cancer Lett. 2003;202:43–51.
7. Carpentier C, Laigle-Donadey F, Marie Y, Auger N, Benouaich-Amiel A, Lejeune J, et al. Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology. 2006;67:872–4.
8. Shir A, Ogris M, Wagner E, Levitzki A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med. 2006;3:e6.
9. Vauleon E, Auger N, Benouaich-Amiel A, Laigle-Donadey F, Kaloshi G, Lejeune J, et al. The 61 a/g EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet. 2007;172:33–7.
10. Stish BJ, Oh S, Vallera DA. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human il-13 and EGF receptors in a mouse xenograft model. J Neurooncol. 2008;87:51–61.
11. Gadji M, Crous AM, Fortin D, Krcek J, Torchia M, Mai S, et al. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. Eur J Pharmacol. 2009;625:23–30.
12. Ozer BH, Wiepz GJ, Bertics PJ. Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain. Oncogene. 2010;29:855–64.
13. Sjostrom S, Andersson U, Liu Y, Brannstrom T, Broholm H, Johansen C, et al. Genetic variations in EGF and EGFR and glioblastoma outcome. Neuro Oncol. 2010;12:815–21.
14. Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant iii supports survival and growth of glioblastoma cells. Proc Natl Acad Sci U S A. 2011;108:15984–9.
15. Fenton TR, Nathanson D, Ponte De Albuquerque C, Kuga D, Iwanami A, Dang J, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the pten tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A. 2012;109:14164–9.
16. Prabhu A, Sarcar B, Kahali S, Shan Y, Chinnaiyan P. Targeting the unfolded protein response in glioblastoma cells with the fusion protein EGF-suba. PLoS One. 2012;7:e52265.
17. Cornez I, Joel M, Tasken K, Langmoen IA, Glover JC, Berge T. EGF signalling and rapamycin-mediated mtor inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry. J Neurooncol. 2013;112:49–57.
18. Zheng Y, Yang W, Aldape K, He J, Lu Z. Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (vcam-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion. J Biol Chem. 2013;288:31488–95.
19. Li S, Gao Y, Ma W, Guo W, Zhou G, Cheng T, et al. EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside rh2. Tumour Biol. 2014;35:5593–8.
20. Emlet DR, Gupta P, Holgado-Madruga M, Del Vecchio CA, Mitra SS, Han SY, et al. Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant iii. Cancer Res. 2014;74:1238–49.
21. Xiao X, Guo P, Chen Z, El-Gohary Y, Wiersch J, Gaffar I, et al. Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem. 2013;288:8636–46.
22. Ye H, Wu Q, Zhu Y, Guo C, Zheng X. Ginsenoside rh2 alleviates dextran sulfate sodium-induced colitis via augmenting tgfbeta signaling. Mol Biol Rep. 2014;41:5485–90.
23. Kikuchi Y, Sasa H, Kita T, Hirata J, Tode T, Nagata I. Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs. 1991;2:63–7.
24. Tode T, Kikuchi Y, Hirata J, Kita T, Imaizumi E. Nagata I: [inhibitory effects of oral administration of ginsenoside rh2 on tumor growth in nude mice bearing serous cyst adenocarcinoma of the human ovary]. Nihon Sanka Fujinka Gakkai Zasshi. 1993;45:1275–82.
25. Tode T, Kikuchi Y, Kita T, Hirata J, Imaizumi E, Nagata I. Inhibitory effects by oral administration of ginsenoside rh2 on the growth of human ovarian cancer cells in nude mice. J Cancer Res Clin Oncol. 1993;120:24–6.
26. Nakata H, Kikuchi Y, Tode T, Hirata J, Kita T, Ishii K, et al. Inhibitory effects of ginsenoside rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn J Cancer Res. 1998;89:733–40.
27. Tang XP, Tang GD, Fang CY, Liang ZH, Zhang LY. Effects of ginsenoside rh2 on growth and migration of pancreatic cancer cells. World J Gastroenterol. 2013;19:1582–92.
28. Liu J, Shimizu K, Yu H, Zhang C, Jin F, Kondo R. Stereospecificity of hydroxyl group at c-20 in antiproliferative action of ginsenoside rh2 on prostate cancer cells. Fitoterapia. 2010;81:902–5.
29. Li B, Zhao J, Wang CZ, Searle J, He TC, Yuan CS, et al. Ginsenoside rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett. 2011;301:185–92.
30. Oh M, Choi YH, Choi S, Chung H, Kim K, Kim SI, et al. Anti-proliferating effects of ginsenoside rh2 on mcf-7 human breast cancer cells. Int J Oncol. 1999;14:869–75.
31. Choi S, Kim TW, Singh SV. Ginsenoside rh2-mediated g1 phase cell cycle arrest in human breast cancer cells is caused by p15 ink4b and p27 kip1-dependent inhibition of cyclin-dependent kinases. Pharm Res. 2009;26:2280–8.
32. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51:1417–23.
33. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N, et al. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer. 1994;56:72–7.